Zolgensma Loses Orphan Benefit in Germany After 'Very High Sales'
Novartis Calls For Change In How Germany Assesses Orphan Benefit
Zolgensma has exceeded the orphan sales threshold in the six months it has been on the market in Germany and the gene therapy must now undergo a full benefit assessment.
